Immunovant, Inc. Financials

Market Capitalization $3.96 Billion as of Jan. 1, 2025

Valuations Metrics as of Jan. 25, 2025

Trailing PE	-12.26
Forward PE	-7.72
Price to Sales TTM	$
Price to Book MRQ	$7.64
Enterprise to Revenue
Enterprise to EBITDA	-8.41

Financial Reports as of Sep. 30, 2024

Financials

Fiscal Year Ends	2024-03-31
Most Recent Quarter	2024-09-30
Profit Margin	0.00%
Operating Margin	0.00%
Return on Assets TTM	-54.54%
Return on Equity TTM	-92.17%

Income Statement

Revenue TTM	$0
Revenue per Share TTM	$0.00
Quarterly Revenue Growth	%
Gross Profit TTM	$0
EBITDA	$-352,164,992
Net Income to Common TTM	$-323,006,016
Diluted EPS TTM	$-2.21
Quarterly Earnings Growth YoY	%

Balance Sheet

Total Cash MRQ	$472,940,992
Total Cash per Share MRQ	$3.22
Total Debt MRQ	$
Total Debt to Equity MRQ	0.01
Current Ratio MRQ	7.61
Book Value per Share MRQ	$3.06

Cash Flow

Operating Cash Flow TTM	$-271,643,008
Levered Free Cash Flow TTM	$-160,827,008

IMVT Stock Info as of Jan. 25, 2025

Stock Statistics

Shares Outstanding	169,284,992
Float Shares	65,671,447
Avg 10 Volume	1,271,020
Avg 30 Volume	None
Shares Short	12,260,769
Short Ratio	12.60
Short % of Shares	19.04%
% Held by Insiders	67.23%
% Held by Institutions	54.57%

Stock Price Summary

Beta	0.71
Fifty Two Week Low	$22.41
Fifty Two Week High	$39.55
Fifty Two Week Change	-70.59%
Day 50 MA	$26.34
Day 200 MA	$28.37

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date